bs-0938R-Biotin [Conjugated Primary Antibody]
KLRK1 Polyclonal Antibody, Biotin Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: KLRK1

Immunogen Range: 121-219/219


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 24934

Swiss Prot: O70215

Source: KLH conjugated synthetic peptide derived from rat KLRK1

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

Function as an activating and costimulatory receptor involved in immunosurveillance upon binding to various cellular stress-inducible ligands displayed at the surface of autologous tumor cells and virus-infected cells. Provides both stimulatory and costimulatory innate immune responses on activated killer (NK) cells, leading to cytotoxic activity. Acts as a costimulatory receptor for T-cell receptor (TCR) in CD8(+) T-cell-mediated adaptive immune responses by amplifying T-cell activation. Stimulates perforin-mediated elimination of ligand-expressing tumor cells. Signaling involves calcium influx, culminating in the expression of TNF-alpha. Participates in NK cell-mediated bone marrow graft rejection. May play a regulatory role in differentiation and survival of NK cells. Binds to ligands belonging to various subfamilies of MHC class I-related glycoproteins.

Conjugation: Biotin

Excitation/ Emission: N/A

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)

Predicted Molecular Weight: 25


Cross Reactive Species: Mouse

Predicted Cross Reactive Species: Human
Rat

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Long Y et al. Downregulation of MCT 4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.Cancer Med. 2018 Sep;7(9):4690-4700. Read more>>
  • Mozer-Lisewska, Iwona, et al. "Detection and Significance of Cytotoxic Cell Subsets in Biopsies of HCV-Infected Human Livers." Archivum immunologiae et therapiae experimentalis (2013): 1-8.Read more>>
  • Onishi,Hideya, et al. "Random Migration Contributes to Cytotoxicity of Activated CD8+ T-Lymphocytes But Not NK cells." Anticancer Research 34.8 (2014): 3947-3956.Read more>>
  • Song et al. Synergistic anti-tumor effects of dasatinib and dendritic cell vaccine on metastatic breast cancer in a mouse model. (2018) Oncol.Lett. 15:6831-6838Read more>>
  • Long et al. Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma. (2018) Cancer.Med. 7:4690-4700Read more>>
  • Long Y et al. Downregulation of MCT 4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma.Cancer Med. 2018 Sep;7(9):4690-4700. Read more>>
  • Meng H et al. ZG16 regulates PD-L1 expression and promotes local immunity in colon cancerTransl Oncol.2021 Feb;14(2):101003.Read more>>
  • Cai, Baohuan. et al. IRAK1-regulated IFN- signaling induces MDSC to facilitate immune evasion in FGFR1-driven hematological malignancies. Mol Cancer. 2021 Dec;20(1):1-2Read more>>
  • Young Min Chung. et al. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. J Immunother Cancer. 2021 Dec;9(12):e002772Read more>>
  • Young Min Chung. et al. FOXO3-dependent suppression of PD-L1 promotes anticancer immune responses via activation of natural killer cells. Am J Cancer Res. 2022; 12(3): 12411263Read more>>
  • Yao Lei. et al. Phytochemical natural killer cells reprogram tumor microenvironment for potent immunotherapy of solid tumors. BIOMATERIALS. 2022 Jun;:121635Read more>>
  • Wang Zhiren. et al. Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy. NAT COMMUN. 2023 Nov;14(1):1-18Read more>>
  • Chen Hsien-Chung. et al. Progesterone boosts abiraterone-driven target and NK cell therapies against glioblastoma. J EXP CLIN CANC RES. 2024 Dec;43(1):1-17Read more>>